Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.

NCT07483970 is registered in ClinicalTrials.gov with Jecho Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07483970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07483970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.
Lead sponsor
Jecho Biopharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
May 18, 2026
Completion date
March 30, 2028
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk non-muscle invasive bladder cancer